VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
-16.95%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.4B
AUM Growth
-$286M
(-17%)
Cap. Flow
-$95.2M
Cap. Flow
% of AUM
-6.8%
Top 10 Holdings %
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23
Top Buys
| 1 |
Arcellx
ACLX
|
+$125M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$50.3M |
| 3 |
Scholar Rock
SRRK
|
+$41.8M |
| 4 |
Vera Therapeutics
VERA
|
+$34.2M |
| 5 |
Nuvalent
NUVL
|
+$33.7M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$120M |
| 2 |
Merck
MRK
|
+$79.6M |
| 3 |
Ascendis Pharma
ASND
|
+$57.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$56.5M |
| 5 |
Soleno Therapeutics
SLNO
|
+$47.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ventyx Biosciences
VTYX
$170M
| $2.3M | 0.16% |
2,000,000
| – | – |
|
52
Arcturus Therapeutics
ARCT
$484M
| $2.24M | 0.16% |
+211,790
| New | +$2.24M |
|
53
Passage Bio
PASG
$22M
| $2.15M | 0.15% |
305,000
| – | – |
|
54
Fate Therapeutics
FATE
$111M
| $1.99M | 0.14% |
2,515,850
+50,850
| +2% | +$40.2K |
|
55
Alto Neuroscience
ANRO
$105M
| $1.98M | 0.14% |
915,000
| – | – |
|
56
Sutro Biopharma
STRO
$83.3M
| $1.69M | 0.12% |
2,600,000
+30,000
| +1% | +$19.5K |
|
57
enGene Holdings
ENGN
$265M
| $1.66M | 0.12% |
370,000
| – | – |
|
58
Alector
ALEC
$279M
| $621K | 0.04% |
+504,540
| New | +$621K |
|
59
Atara Biotherapeutics
ATRA
$85.5M
| $559K | 0.04% |
94,085
-30,915
| -25% | -$184K |
|
60
Traws Pharma
TRAW
$13.1M
| $403K | 0.03% |
175,000
+100,000
| +133% | +$230K |
|
61
MacroGenics
MGNX
$111M
| $356K | 0.03% |
280,000
| – | – |
|
62
Tenax Therapeutics
TENX
$27.6M
| $350K | 0.03% |
53,439
-1,750
| -3% | -$11.5K |
|
|
CNTA
63
Centessa Pharmaceuticals
CNTA
$2.11B
| $214K | 0.02% |
+14,888
| New | +$214K |
|
64
Agilent Technologies
A
$36.3B
| – | – |
-75,000
| Closed | -$10.1M |
|
65
Allogene Therapeutics
ALLO
$253M
| – | – |
-1,500,000
| Closed | -$3.2M |
|
66
AstraZeneca
AZN
$253B
| – | – |
-475,000
| Closed | -$31.1M |
|
67
Bausch Health
BHC
$2.71B
| – | – |
-250,000
| Closed | -$2.02M |
|
|
68
BioMarin Pharmaceuticals
BMRN
$10.8B
| – | – |
-860,000
| Closed | -$56.5M |
|
69
Monte Rosa Therapeutics
GLUE
$305M
| – | – |
-425,000
| Closed | -$2.95M |
|
70
GSK
GSK
$80.6B
| – | – |
-1,000,000
| Closed | -$33.8M |
|
71
Ionis Pharmaceuticals
IONS
$9.72B
| – | – |
-595,000
| Closed | -$20.8M |
|
|
72
Jazz Pharmaceuticals
JAZZ
$7.88B
| – | – |
-975,000
| Closed | -$120M |
|
73
Legend Biotech
LEGN
$6.39B
| – | – |
-475,000
| Closed | -$15.5M |
|
74
Madrigal Pharmaceuticals
MDGL
$10.1B
| – | – |
-95,000
| Closed | -$29.3M |
|
|
75
Merck
MRK
$210B
| – | – |
-800,000
| Closed | -$79.6M |
|